Global News

Making the most of media outreach

Monday, March 7, 2016

The Pulse on Patient Recruitment by Ashley Tointon

Due to the proliferation of clinical research studies and shortened timelines for recruitment, more studies depend on outreach activities to fill the gap between the number of participants needed in a research study and the number of participants a site can recruit within their own network. Media outreach is a ubiquitous tactic occasionally deployed to fill this gap, but it is often met with mixed results. 

[Read More]

Sanofi releases phase I/II Pompe disease study results

Friday, March 4, 2016

Sanofi and its specialty care global business unit Sanofi Genzyme have presented data from NEO1, its phase I/II clinical study evaluating the investigational novel enzyme replacement therapy neoGAA in 24 patients with late-onset Pompe disease. The safety and efficacy data from this study support further development of the therapy. Sanofi Genzyme plans to begin enrolling patients in a pivotal phase III trial for neoGAA in Q2 2016.

[Read More]

2015 Discovery Fast Track Challenge winners announced by GSK

Friday, March 4, 2016

GlaxoSmithKline has announced the winners of its third Discovery Fast Track Challenge. The program is sponsored by GSK’s Discovery Partnerships with Academia (DPAc) group to provide an opportunity for academic researchers in Europe and North America to collaborate with GSK and explore novel ideas for potential medicines. Six winning proposals were selected from 378 entries submitted from 21 countries across Europe and North America. The selected proposals cover research related to discovery of potential new treatments for cancer, inflammatory bowel disease, HIV and kidney disease.

[Read More]

WIRB-Copernicus develops ethics tool kit for clinical research protocols

Wednesday, March 2, 2016

WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services and software to support clinical research, has announced the publication of an innovative Ethics Tool Kit in the Journal of Medical Ethics. Developed by the Multi-Regional Clinical Trials (MRCT) Center of Harvard and Brigham and Women’s Hospital working group, the toolkit was co-written by 20 experts in clinical research, including WCG Chief Medical Officer and President of Consulting Services Lindsay McNair, M.D., MPH, MSB, and WCG Chief Compliance Officer David Forster, JD, MA, CIP.

[Read More]

Andrew Lloyd & Associates, Adebiotech partner for innovation

Wednesday, March 2, 2016

Andrew Lloyd & Associates (ALA), an international public relations group for companies and organizations working in life sciences and innovative technologies, and Adebiotech, an independent cross-disciplinary think-tank for biotechnology in France, have signed a partnership agreement to promote interdisciplinary discussion and innovation in the field of biotechnology. In particular, this partnership aims to raise awareness of Adebiotech’s activities amongst specialist audiences interested in developments concerning human and animal health, the environment, energy, food processing, cosmetics, processes and industrial systems, amongst others.

[Read More]

Survey: Need for increased consumer clinical trials education

Wednesday, March 2, 2016

SubjectWell, provider of a risk-free patient recruitment marketplace for clinical trials, has released its report on consumer perceptions of clinical trials. The SubjectWell Survey of Clinical Trial Awareness and Attitudes reveals significant education is still needed around the existence of clinical trials. Half of those surveyed (50%) had never heard of clinical trials, and only 31% felt confident or very confident that they would know how to get information about clinical trials. 

[Read More]

The CenterWatch Monthly, March 2016

Tuesday, March 1, 2016

Slow to negative growth in select emerging markets

A few years ago, Latin America and India were considered among the most promising emerging markets for conducting industry-sponsored clinical trials. Dramatic increases were predicted for both regions, and investigative sites anticipated an influx of new work. Unfortunately, growth in these markets has fallen far short of expectations. The number of industry-sponsored global phase I-IV trials in India has dropped 22.4% annually between 2010 and 2014, according to the 2015/2016 Parexel Biopharmaceutical R&D Statistical Sourcebook’s analysis of the ClinicalTrials.gov database.

monthly chart

CROs juggle proprietary and commercial systems

Third-party vendors have come to dominate the clinical trial technology sector, which was led by CROs a decade ago. At the same time, many large CROs continue to invest in technology solutions to differentiate their services and offer greater efficiencies in clinical development processes. The eClinical solutions market, which includes electronic data capture (EDC) and clinical trial management systems (CTMS), could generate total global sales of $5 billion by 2018, representing a five-year annual growth rate of 13.5%, according to a recent report from global market research company MarketsandMarkets. Yet much of the growth in clinical trial technologies is expected to come from niche providers rather than in-house systems developed by CROs.

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Report: Breast cancer has over 1,000 drugs in development

Tuesday, March 1, 2016

The breast cancer treatment pipeline’s exceptional levels of activity and innovation, with a staggering 1,050 drugs in active development across all stages and 347 first-in-class programs, may significantly alter the clinical and commercial landscape of the disease market over the next decade, according to business intelligence provider GBI Research.

[Read More]